TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01601704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB32
Description: Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PBO
Description: Placebo. Administered in addition to the weight management program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management Program
Description: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight Management Program
Description: A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
Study: NCT02841592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flush rate oxygen
Description: Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flush rate oxygen with assist
Description: Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
Study: NCT00212212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: 200 µg selenium as selenate
Study: NCT03263065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: 220g rice pudding meal with raspberry jam with added psyllium flakes
Study: NCT04405921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine 200 Mg Oral Tablet
Description: orally or via gastric tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 MG
Description: orally or via gastric tube
Study: NCT02253459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTD1 Injection plus capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT03760354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
Study: NCT00212212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: 400 µg selenium as selenate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: 200 µg selenium as selenomethionine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study: NCT04144738

Intervention type: DIAGNOSTIC_TEST
Intervention: mt-sDNA 2.0 screening test
Description: Stool samples will be collected by the subject for the mt-sDNA screening test.
Study: NCT01620671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair of perforated peptic ulcer
Description: Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair of perforated peptic ulcer
Description: Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
Study: NCT02925208

Intervention type: OTHER
Intervention: cochlear implant surgery
Description: patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
Study: NCT02814448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CryoPen
Description: Provides a means of freezing tissue without the use of gases or liquids
Study: NCT03756467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girl Empower Program
Description: Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
Study: NCT02814448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CryoPen
Description: Provides a means of freezing tissue without the use of gases or liquids

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 standard cryotherapy
Description: Standard therapy using carbon dioxide for freezing of tissue
Study: NCT03756467

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Girl Empower Program
Description: Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
Study: NCT03482349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Robotically-Assisted
Description: The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
Study: NCT04713150

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT04144738

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT test
Description: Stool samples will be collected by the subject for the FIT test.
Study: NCT02916043

Intervention type: PROCEDURE
Intervention: Cardiovascular surgery with cardiopulmonary bypass
Description: Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
Study: NCT03993730

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD
Description: Insertion of ICD in patients with LVEF \<45% and LGE on CMR.

Intervention type: DEVICE
Group type: OTHER
Intervention: ILR
Description: Insertion of ILR in patients with LVEF \<45% and LGE on CMR.
Study: NCT01088802

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
Study: NCT02814448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 standard cryotherapy
Description: Standard therapy using carbon dioxide for freezing of tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocoagulator
Description: The use of heat produced by high-frequency electric current to bring about local destruction of tissues
Study: NCT05278767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Mobile Education and Counselling
Description: The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
Study: NCT04396678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP standard of care+behavioral intervention
Description: The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
Study: NCT01142349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyles A
Description: Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyles B
Description: Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyles C
Description: Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
Study: NCT02438332

Intervention type: DEVICE
Intervention: Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants
Description: Surgical implant
Study: NCT02969694

Intervention type: OTHER
Intervention: G-STAT questionnaire
Description: Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction.
Study: NCT00243685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Assay
Description: Chemotherapy
Study: NCT02438332

Intervention type: DEVICE
Intervention: Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants
Description: surgical implant
Study: NCT01088802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
Study: NCT02438332

Intervention type: DEVICE
Intervention: Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants
Description: surgical implant

Intervention type: DEVICE
Intervention: Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants
Description: surgical implant
Study: NCT01511198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Injected subcutaneously once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000 mg twice daily, administered orally
Study: NCT00243685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mick Assay
Description: Chemotherapy doctor determined from results
Study: NCT00462618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Study: NCT00351819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel
Description: 5g gel, applied once daily to the upper arms, upper back or shoulders.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g gel, applied once daily to the upper arms, upper back or shoulders.
Study: NCT00992524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
Study: NCT06314997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab (EGFR inhibitors)
Description: Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab (EGFR inhibitors)
Description: Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab (EGFR inhibitors)
Description: Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
Study: NCT04410081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-lazertinib
Description: A single oral dose of 14C-lazertinib will be administered.
Study: NCT03101527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Description: Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
Study: NCT00562016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMPLELLA LP 2.5
Description: Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
Study: NCT00992524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Vaginal tablets will have 25mcg of misoprostol or placebo.
Study: NCT00562016

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IABP Intra-aortic balloon pump
Description: IABP uses counterpulsation to provide 0.2L/min coronary flow
Study: NCT02866734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free screening group
Description: The intervention provide Diabetic Retinopathy screening without charging a fee.
Study: NCT04295135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pain OneSheet
Description: The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. OneSheet works by aggregating and structuring information that is already collected, that PCPs often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of OneSheet is to make the information that is important in clinical decision making more readily available, and to reduce the amount of time that PCPs need to spend locating this information.
Study: NCT00134043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT00596037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone - LB03002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone - LB03002
Study: NCT04644874

Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric 8
Description: The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.

Intervention type: DIAGNOSTIC_TEST
Intervention: modified Geriatric 8
Description: The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.

Intervention type: DIAGNOSTIC_TEST
Intervention: 30 second chair stand test
Description: Repetitions within 30 seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: Handgrip Strength Test
Description: Measured in kilograms
Study: NCT04236726

Intervention type: OTHER
Intervention: Questionnaire
Description: HRQoL questionnaires
Study: NCT01072955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine Heparin
Description: 5.000UI/mL bottle with 5mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Porcine heparin
Description: 5000 USP Heparin Units / mL vial with 10 mL vial
Study: NCT02866734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pay screening group ($150)
Description: The intervention is charging HK$150 for the Diabetic Retinopathy screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pay screening group ($300)
Description: The intervention is charging HK$300 for the Diabetic Retinopathy screening.
Study: NCT05521139

Intervention type: DIAGNOSTIC_TEST
Intervention: drug sensitivity results
Description: drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae

Intervention type: DIAGNOSTIC_TEST
Intervention: drug sensitivity results
Description: drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
Study: NCT03760354

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
Study: NCT04386772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVE with coils plus TAGM
Description: PVE with TAGM distally and coils proximally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on future liver remnant (FLR) side for patients with pCCA when obstructive jaundice is present.
Study: NCT00805753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: comparison of different dosages of drug
Study: NCT02056392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Volunteers will receive 75 mg selumetinib oral dose (Treatment A)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: selumetinib placebo
Description: Volunteers will receive selumetinib placebo oral dose (Treatment C)
Study: NCT03416244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV fixed dose every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV fixed dose every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
Study: NCT04386772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVE with multiple coils
Description: Procedure: PVE with multiple coils PVE with multiple coils proximally and distally and subsequent scheduled major hepatectomy. Sequential transcatheter arterial chemoembolization and PVE for patients with HCC. Selective biliary drainage on FLR side for patients with pCCA when obstructive jaundice is present.
Study: NCT00000936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hOKT3
Description: Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
Study: NCT02408068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone used to suppress endogenous cortisol secretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone used to suppress endogenous cortisol secretion
Study: NCT04144738

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Subjects will undergo a screening colonoscopy.
Study: NCT03111004

Intervention type: OTHER
Intervention: New Care
Description: All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
Study: NCT03355248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Acetaminophen
Description: Decrease in opioid prescribing for post-operative cesarean pain management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxycodone Acetaminophen
Description: Decrease in opioid prescribing for post-operative cesarean pain management
Study: NCT00682175

Intervention type: OTHER
Intervention: Observational
Description: Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
Study: NCT03519399

Intervention type: DEVICE
Intervention: Monica AN24
Description: Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
Study: NCT00358033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacologic case management
Description: Provided by clinical pharmacists

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacologic case management
Description: Provided by clinical pharmacists
Study: NCT04335630

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram, telemetry, echocardiogram, laboratory values
Description: Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram, telemetry, echocardiogram, laboratory values
Description: Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
Study: NCT00572429

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: l-carnitine
Description: 3 gram daily dose